B-cell lymphoma

FDA-Approved Treatments

• Tositumomab and iodine I 131 tositumomab (Brand name: Bexxar®) - Manufactured by GlaxoSmithKline
  FDA-approved indication: Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy
  National Library of Medicine Drug Information Portal
  Medline Plus Health Information
• Pembrolizumab (Brand name: Keytruda) - Manufactured by Merck, Sharp & Dohme Corp.
  FDA-approved indication: June 2018 approved for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy.
  National Library of Medicine Drug Information Portal
  Medline Plus Health Information
• Tisagenlecleucel-T (Brand name: Kymriah) - Manufactured by Novartis Pharmaceuticals Corporation
  FDA-approved indication: May 2018, KYMRIAH is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of patients with diffuse large B-cell lymphoma, high-grade B-cell lymphoma, or DLBCL arising from follicular lymphoma who received two or more lines of systemic therapy.
  National Library of Medicine Drug Information Portal
  Medline Plus Health Information
• Rituximab (Brand name: Rituxan® (injection)) - Manufactured by Genentech, Inc.
  FDA-approved indication: Treatment of non-Hodgkin's B-cell lymphoma.
  National Library of Medicine Drug Information Portal
  Medline Plus Health Information
• Venetoclax (Brand name: Venclexta) - Manufactured by AbbVie Inc.
  FDA-approved indication: June 2018, venetoclax (Venclexta) received expanded approval for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.
  National Library of Medicine Drug Information Portal
  Medline Plus Health Information
• Ibritumomab tiuxetan (Brand name: Zevalin) - Manufactured by Cell Therapeutics, Inc.
  FDA-approved indication: Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan) refractory follicular non-Hodgkin's lymphoma.
  National Library of Medicine Drug Information Portal
  Medline Plus Health Information
• idelalisib (Brand name: Zydelig) - Manufactured by Gilead Sciences, Inc
  FDA-approved indication: (1) Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and (2) Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies; and (3) Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.
  National Library of Medicine Drug Information Portal

Research helps us better understand diseases and can lead to advances in diagnosis and treatment. This section provides resources to help you learn about medical research and ways to get involved.

Support and advocacy groups can help you connect with other patients and families, and they can provide valuable services. Many develop patient-centered information and are the driving force behind research for better treatments and possible cures. They can direct you to research, resources, and services. Many organizations also have experts who serve as medical advisors or provide lists of doctors/clinics. Visit the group’s website or contact them to learn about the services they offer. Inclusion on this list is not an endorsement by GARD.

These resources provide more information about this condition or associated symptoms. The in-depth resources contain medical and scientific language that may be hard to understand. You may want to review these resources with a medical professional.